| DOI | Resolve DOI: https://doi.org/10.1007/s00044-011-9759-1 |
|---|
| Author | Search for: Bartusik, Dorota1; Search for: Tomanek, Boguslaw1 |
|---|
| Affiliation | - National Research Council of Canada. NRC Institute for Biodiagnostics
|
|---|
| Format | Text, Article |
|---|
| Subject | magnetic resonance imaging; breast cancer cells; drug efficacy |
|---|
| Abstract | This study is aimed on Magnetic resonance imaging (MRI) modalities for monitoring Herceptin (trastuzumab) efficacy in breast cancer cells ex vivo. The efficacy profile of trastuzumab (0.010 μg/ml) was examined using T2 relaxivity measurements prior to and after 24, 48, and 72 h treatment. The untreated MCF-7 cells were considered as a control. MRI results show early tumor response to treatment while comparing pre- and post-treatment T2. The changes of T2 MRI correspond to tumor growth inhibition. The study shows that MRI can be used for the non-invasive monitoring of cancer cells’ death caused by immuno-targeting in preclinical testing of efficacy and treatment regimens. |
|---|
| Publication date | 2011-08-02 |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Identifier | 9759 |
|---|
| NPARC number | 21268252 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | d7d49b8e-ab2a-4267-846a-c6753bd9dda6 |
|---|
| Record created | 2013-06-10 |
|---|
| Record modified | 2020-04-21 |
|---|
